JP2011524745A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011524745A5 JP2011524745A5 JP2011512892A JP2011512892A JP2011524745A5 JP 2011524745 A5 JP2011524745 A5 JP 2011524745A5 JP 2011512892 A JP2011512892 A JP 2011512892A JP 2011512892 A JP2011512892 A JP 2011512892A JP 2011524745 A5 JP2011524745 A5 JP 2011524745A5
- Authority
- JP
- Japan
- Prior art keywords
- building blocks
- oligonucleotide molecule
- hrp
- nucleotide
- poly
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108091034117 Oligonucleotide Proteins 0.000 claims 11
- 125000003729 nucleotide group Chemical group 0.000 claims 10
- 239000002773 nucleotide Substances 0.000 claims 6
- 102100039389 Hepatoma-derived growth factor-related protein 3 Human genes 0.000 claims 5
- 101710161031 Hepatoma-derived growth factor-related protein 3 Proteins 0.000 claims 5
- 230000033115 angiogenesis Effects 0.000 claims 3
- 238000003745 diagnosis Methods 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical group OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims 2
- 102100031000 Hepatoma-derived growth factor Human genes 0.000 claims 2
- 102000009353 PWWP domains Human genes 0.000 claims 2
- 108050000223 PWWP domains Proteins 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 125000002637 deoxyribonucleotide group Chemical group 0.000 claims 2
- 108010052188 hepatoma-derived growth factor Proteins 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 229920001223 polyethylene glycol Polymers 0.000 claims 2
- 125000002652 ribonucleotide group Chemical group 0.000 claims 2
- 125000006850 spacer group Chemical group 0.000 claims 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 1
- 108091023037 Aptamer Proteins 0.000 claims 1
- 102000053642 Catalytic RNA Human genes 0.000 claims 1
- 108090000994 Catalytic RNA Proteins 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 108020004635 Complementary DNA Proteins 0.000 claims 1
- 102100031017 Hepatoma-derived growth factor-like protein 1 Human genes 0.000 claims 1
- 102100031001 Hepatoma-derived growth factor-related protein 2 Human genes 0.000 claims 1
- 101710161030 Hepatoma-derived growth factor-related protein 2 Proteins 0.000 claims 1
- 101001083786 Homo sapiens Hepatoma-derived growth factor-like protein 1 Proteins 0.000 claims 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 102100036220 PC4 and SFRS1-interacting protein Human genes 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 108091030071 RNAI Proteins 0.000 claims 1
- 108091028664 Ribonucleotide Proteins 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 238000011374 additional therapy Methods 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 230000000692 anti-sense effect Effects 0.000 claims 1
- -1 antisense molecule Proteins 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 239000005547 deoxyribonucleotide Substances 0.000 claims 1
- 238000007877 drug screening Methods 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 230000009368 gene silencing by RNA Effects 0.000 claims 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 1
- 230000003463 hyperproliferative effect Effects 0.000 claims 1
- 108010093345 lens epithelium-derived growth factor Proteins 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 230000005855 radiation Effects 0.000 claims 1
- 239000002336 ribonucleotide Substances 0.000 claims 1
- 108091092562 ribozyme Proteins 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US6057108P | 2008-06-11 | 2008-06-11 | |
| US61/060,571 | 2008-06-11 | ||
| PCT/EP2009/004186 WO2009149921A2 (en) | 2008-06-11 | 2009-06-10 | Inhibition of hrp-3 using modified oligonucleotides |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011524745A JP2011524745A (ja) | 2011-09-08 |
| JP2011524745A5 true JP2011524745A5 (enExample) | 2012-07-12 |
| JP5559159B2 JP5559159B2 (ja) | 2014-07-23 |
Family
ID=41130624
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011512892A Expired - Fee Related JP5559159B2 (ja) | 2008-06-11 | 2009-06-10 | 修飾オリゴヌクレオチドを使用するｈｒｐ−３の阻害 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US8710021B2 (enExample) |
| EP (1) | EP2304031A2 (enExample) |
| JP (1) | JP5559159B2 (enExample) |
| AU (1) | AU2009256906A1 (enExample) |
| CA (1) | CA2727285A1 (enExample) |
| WO (1) | WO2009149921A2 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2558578B1 (en) | 2010-04-13 | 2015-10-28 | Life Technologies Corporation | Compositions and methods for inhibition of nucleic acids function |
| WO2015046783A1 (en) * | 2013-09-30 | 2015-04-02 | Korea Institute Of Radiological & Medical Sciences | Pharmaceutical composition for treatment of radiation- or drug-resistant cancer comprising hrp-3 inhibitor |
| GB201410693D0 (en) | 2014-06-16 | 2014-07-30 | Univ Southampton | Splicing modulation |
| EP3201339A4 (en) | 2014-10-03 | 2018-09-19 | Cold Spring Harbor Laboratory | Targeted augmentation of nuclear gene output |
| AU2016334804B2 (en) | 2015-10-09 | 2022-03-31 | University Of Southampton | Modulation of gene expression and screening for deregulated protein expression |
| US11096956B2 (en) | 2015-12-14 | 2021-08-24 | Stoke Therapeutics, Inc. | Antisense oligomers and uses thereof |
| ES2882500T3 (es) | 2015-12-14 | 2021-12-02 | Cold Spring Harbor Laboratory | Oligómeros antisentido para el tratamiento del síndrome de Dravet |
| SI3673080T1 (sl) | 2017-08-25 | 2024-03-29 | Stoke Therapeutics, Inc. | Protismiselni oligomeri za zdravljenje bolezenskih stanj in bolezni |
| WO2019213525A1 (en) | 2018-05-04 | 2019-11-07 | Stoke Therapeutics, Inc. | Methods and compositions for treatment of cholesteryl ester storage disease |
| KR20210134003A (ko) | 2019-02-27 | 2021-11-08 | 스톡 테라퓨틱스, 인크. | 병태 및 질환의 치료를 위한 안티센스 올리고머 |
| BR112022022889A2 (pt) | 2020-05-11 | 2023-04-04 | Stoke Therapeutics Inc | Oligômeros antissentido de opa1 para tratamento de condições e doenças |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI946201A0 (fi) * | 1992-07-02 | 1994-12-30 | Hybridon Inc | Itsestabiloidut oligonukleotidit terapeuttisina aineina |
| US6699843B2 (en) * | 1995-06-07 | 2004-03-02 | Gilead Sciences, Inc. | Method for treatment of tumors using nucleic acid ligands to PDGF |
| US6893844B1 (en) | 1998-09-22 | 2005-05-17 | Long Yu | DNA encoding a new human hepatoma derived growth factor and producing method thereof |
| US20030198953A1 (en) | 2000-03-30 | 2003-10-23 | Spytek Kimberly A. | Novel proteins and nucleic acids encoding same |
| WO2004015075A2 (en) | 2002-08-08 | 2004-02-19 | Dharmacon, Inc. | Short interfering rnas having a hairpin structure containing a non-nucleotide loop |
| GB0321805D0 (en) | 2003-09-18 | 2003-10-15 | Univ Wales Medicine | Human tumour growth patterns |
| EP1526177A1 (en) | 2003-10-24 | 2005-04-27 | Institut Curie | Nucleic acids useful for triggering tumor cell lethality |
| EP1737879B1 (en) * | 2004-04-19 | 2012-10-10 | Archemix LLC | Aptamer-mediated intracellular delivery of therapeutic oligonucleotides |
| AU2005259381A1 (en) | 2004-07-02 | 2006-01-12 | Creabilis Therapeutics S.P.A. | Nucleic acids for the treatment of HMGB1-related pathologies |
| MEP0208A (xx) * | 2005-08-26 | 2010-02-10 | Archemix Corp | Aptameri koji vezuje trombin sa visokim afininitetom |
| EP1978985A2 (en) | 2005-12-23 | 2008-10-15 | Board Of Regents Of The University Of Texas System | Anti-hyperproliferative therapies targeting hdgf |
| EP1984501B1 (en) * | 2006-02-14 | 2011-05-18 | Noxxon Pharma AG | Mcp-i binding nucleic acids |
| US8367629B2 (en) * | 2006-02-14 | 2013-02-05 | Noxxon Pharma Ag | MCP-1 binding nucleic acids and use thereof |
| EP2041282B1 (en) * | 2006-07-18 | 2018-01-03 | Noxxon Pharma AG | Sdf-i binding nucleic acids |
-
2009
- 2009-06-10 EP EP09761484A patent/EP2304031A2/en not_active Withdrawn
- 2009-06-10 AU AU2009256906A patent/AU2009256906A1/en not_active Abandoned
- 2009-06-10 US US12/997,720 patent/US8710021B2/en not_active Expired - Fee Related
- 2009-06-10 CA CA2727285A patent/CA2727285A1/en not_active Abandoned
- 2009-06-10 JP JP2011512892A patent/JP5559159B2/ja not_active Expired - Fee Related
- 2009-06-10 WO PCT/EP2009/004186 patent/WO2009149921A2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ni et al. | Chemical modifications of nucleic acid aptamers for therapeutic purposes | |
| TWI784934B (zh) | 抑制lpa之基因表現之組合物及方法 | |
| ES2857702T3 (es) | Oligonucleótidos para la reducción de la expresión de PD-L1 | |
| US8440637B2 (en) | Combination treatment for the treatment of hepatitis C virus infection | |
| JP2014527401A5 (enExample) | ||
| US20180179521A1 (en) | Modified crispr rna and modified single crispr rna and uses thereof | |
| JP7515400B2 (ja) | Ｂ型肝炎ウイルス感染を治療するためのｆｕｂｐ１阻害剤の使用 | |
| US9725715B2 (en) | Signal activatable constructs and related components compositions methods and systems | |
| CN105008533A (zh) | 嵌合单链反义多核苷酸和双链反义试剂 | |
| JP2010524486A (ja) | β−カテニンを調節するためのＲＮＡアンタゴニスト化合物 | |
| JP5559159B2 (ja) | 修飾オリゴヌクレオチドを使用するｈｒｐ−３の阻害 | |
| TW202408542A (zh) | 製備環狀ｒｎａ的方法 | |
| Romanucci et al. | Hairpin oligonucleotides forming G-quadruplexes: New aptamers with anti-HIV activity | |
| CN119604311A (zh) | FN3结构域-siRNA缀合物与酶替代疗法 | |
| Varizhuk et al. | G4 aptamers: trends in structural design | |
| US20230340496A1 (en) | Aptamer template and method for preparing aptamer by using same | |
| JP2025039668A (ja) | Ｒｔｅｌ１発現の調節用のオリゴヌクレオチド | |
| US20150353933A1 (en) | Aptamer against midkine and applications thereof | |
| CN118984717A (zh) | Arnatar化合物和用于增强细胞摄取的方法 | |
| WO2021122735A1 (en) | Use of sept9 inhibitors for treating hepatitis b virus infection | |
| Shearer et al. | The clinical potential of l-oligonucleotides: challenges and opportunities | |
| CN113728102A (zh) | 使用剪接调节化合物进行新抗原工程化 | |
| CN111212909A (zh) | 用于抑制去唾液酸糖蛋白受体1的表达的RNAi试剂和组合物 | |
| JP2023506540A (ja) | Ｂ型肝炎ウイルス感染を処置するためのｓｃａｍｐ３阻害剤の使用 | |
| EP3124611B1 (en) | Aptamer for fgf2 and use thereof |